백혈병 미세잔존질환 정량검출을 위한 실시간 역전사중합효소연쇄반응법의 유용성
Utility of Real Time RT-PCR for the Quantitative Detection of Minimal Residual Disease in Hematological Malignancy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
.
Abstract
Chromosomal rearrangements are major pathology in hematological malignancies. The detection of minimal residual disease (MRD) for these gene rearrangements helps in monitoring treatment outcomes and predicting prognosis of patients. Recently, quantification of these gene transcripts based on real-time quantitative polymerase chain reaction (RQ-PCR) has been used as MRD detection. The purpose of this study is to ensure the usefulness of the RQ-PCR technique for detecting MRD in hamatological malignancy patients. The patients had been diagnosed to AML1-ETO positive AML, PML-RARa positive AML and BCR-ABL positive MPN at Chonnam National University Hwasun Hospital from Jan. 2006 to Aug. 2008. The fusion transcript was quntified by RQ-PCR and analyzed in comparison to conventional cytogenetics, FISH and RT-PCR. The fusion gene transcript was quantified by RQ-PCR in 57 samples from 14 patients with AML1-ETO positive AML, 79 samples from 27 patients with PML-RARa positive AML and 108 samples from 36 patients with CML. At diagnosis, the quantitative fusion transcripts for AM1-ETO, PML-RARa and BCR-ABL showed the range of 0.485552651~10.82233683 (mean 3.782217131, SD 2.998052348), 0.005300395~0.29267494 (mean 0.056901315, SD 0.080131381) and 0.1293929~12.94826849 (mean 1.701935665, SD 2.200913158). The increase of AML1-ETO fusion gene transcripts preceded morphologic relapse in two patients. Quantification of fusion gene transcripts by RQ-PCR could detected MRD in samples which were negative by in cytogenetics analysis or FISH. Our findings indicated that quantitative analysis of AML1-ETO, PML-RARa and BCR-ABL transcripts by RQ-PCR might be a useful tool for the monotoring residual disease in hematological malignancies.
참고문헌 (15)
- Bustin SA, "Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems", J Mol Endocrinol, 29, pp.23~39 (2002)
- Santamaria C, "Using quantification of the PML-RARa transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia", Haematologica, 92, pp.315~322 (2007)
- Campana D, "Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance", Blood, 85, pp.1416~1434 (1995)
- Elmaagacli AH, "Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method", Br J Haematol, 113, pp.1072~1075 (2001)
- Emig M, "Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR", Leukemia, 13, pp.1825~1832 (1999)
- Gameiro P, "The PML-RARa transcript in long-term follow-up of acute promyelocytic leukemia patients", Haematologica, 86, pp.577~585 (2001)
- Grimwade D, "Acute promyelocytic leukemia:a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia", Leukemia, 16, pp.1959~1973 (2002)
- Hiroto N, "Clinical significance of minimal residual disease in patients with t(8;21)acute myeloid leukemia in Japan", Int J Hematol, 88, pp.154~158 (2008)
- Ito Y, "Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: Is molecular remission a milestone for achieving a cure?", Leuk Lymphoma, 16, pp.57~64 (1994)
- Negrin RS, "The use of the polymerase chain reaction for the detection of minimal residual malignant disease", Blood, 78, pp.255~258 (1991)
- Preudhomme C, "Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a “real time” quantitative RT-PCR assay", Leukemia, 13, pp.957~964 (1999)
- Shaffer LG, "An international system for human cytogenetic nomen clature" (2005), Karger
- Tobal K, "Monitoring of minimal residual disease by quantitative reverse transcriptase polymerase chain reaction for AML1-MTG8 transcripts in AML M2 with t(8;21)", Blood, 88, pp.3704~3709 (1996)
- van der Velden VH, "Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR : principles, approaches, and laboratory aspects", Leukemia, 17, pp.1013~1034 (2003)
- Weisser M, "The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors", Leukemia, 21, pp.1177~1182 (2007)